Merger of ORGENTEC Diagnostika and Corgenix Medical creates a global distribution network and offers more than 350 diagnostic assays

Mainz, Germany – The global diagnostics industry is welcoming ORGENTEC Diagnostika and Corgenix Medical Corporation to the 2015 American Association of Clinical Chemistry (AACC) Clinical Lab Expo in booth #3711. ORGENTEC completed its acquisition of Corgenix in March 2015 and is exhibiting for the first time at AACC. The combined specialty diagnostics company features a portfolio of more than 350 diagnostic tests, including ELISA, IFA, LFI, IT and immunoblot.

“The AACC conference marks a new and promising beginning for our companies,” said Werner Hofacher, chief executive officer of the combined company. “Both companies are highly innovative with unique offerings that complement each other. Together, we’ll work on our strategic plan to build ORGENTEC into the global industry leader in specialty diagnostics.”

ORGENTEC excels in autoimmune diagnostics with additional capabilities in specialty infectious disease, organ function testing and lab automation. Corgenix offers an extensive cardiovascular diagnostics portfolio along with autoimmune, organ function and infectious disease testing, and has achieved global recognition for its development of the AspirinWorks Test – the world’s only urine-based test for measuring aspirin effect – and for its Ebola and Lassa rapid diagnostic tests developed in collaboration with the Viral Hemorrhagic Fever Consortium.

“We are committed to improving global health care through the development of innovative diagnostic tests targeting a range of conditions, and we look forward to expanding our offerings to even more laboratories, hospitals and patients worldwide,” said Hofacher.

ORGENTEC and Corgenix representatives will be available throughout the expo at booth #3711 to discuss capabilities and answer questions about the newly combined company. Several scientific posters in the infectious disease category will be presented by ORGENTEC and Corgenix researchers; consult the AACC 2015 conference program for full details.


Headquartered in Mainz, Germany, with U.S. operations in Broomfield, Colorado, ORGENTEC offers one of the industry’s most comprehensive portfolios in autoimmune diagnostics and cardiovascular diagnostics with additional strengths in infectious disease, inflammatory rheumatic diseases, thrombotic disorders and organ function testing. The company’s products are supported by a global distribution network, and its line of automated instruments for diagnostics and serology enables labs to complete multiple assays and deliver faster results than traditional analyzers. Additionally, ORGENTEC contract develops and manufactures products for key medical and life science companies.


We use cookies on our website. Some of them are essential for the operation of the site, while others help us to improve this site and the user experience (tracking cookies). You can decide for yourself whether you want to allow cookies or not. Please note that if you reject them, you may not be able to use all the functionalities of the site.